Overview

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
To assess if amrubicin is safe and useful for patients with multiple myeloma requiring additional treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Michaela Liedtke
Collaborator:
Celgene Corporation
Treatments:
Amrubicin
Aspirin
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide
Thalidomide